Document is current
Any future updates will be listed below
-
Authors
Masumori, Naoya
Hosono, Makoto
Takahashi, Shunji
Kakehi, Yoshiyuki
Uemura, Hirotsugu
Sunaya, Toshiyuki
Shimotsumagari, Kako
Matsuba, Yasuhiro
Adachi, Masatoshi
Kakiuchi, Haruka
Kinuya, Seigo
-
Funding
Funding for this research was provided by:
Janssen Japan (honoraria, honoraria)
Astellas Pharma (honoraria)
Bayer Yakuhin (honoraria, research funding, honoraria)
Ono Pharmaceutical (honoraria, honoraria, research funding)
Takeda Pharmaceutical Company (honoraria, honoraria)
Merck Sharp and Dohme K.K. (research funding, honoraria, research funding)
Eisai (honoraria, research funding)
Chugai Pharmaceutical (research funding)
AstraZeneca KK (research funding, honoraria, research funding)
Bristol-Myers Squibb (research funding)
Daiichi-Sankyo (research funding)
Novartis (research funding)
Taiho Pharmaceutical (research funding)
Sanofi K.K. (honoraria)
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 21 July 2025
First Online: 8 August 2025
Declarations
:
: NM received honoraria from Janssen, Astellas, Bayer, Ono Pharmaceutical, and Takeda, and research funding from MSD. ST received honoraria from MSD, Eisai, and Ono Pharmaceutical, and research grants from Eisai, Chugai, Bayer, AstraZeneca, BMS, Ono Pharmaceutical, Daiichi-Sankyo, Novartis, Taiho, and MSD. HU received honoraria from Bayer, Janssen, Takeda, Sanofi and AstraZeneca, and research funding from AstraZeneca. TS, KS, YM, MA, and HK are employees of Bayer Yakuhin, Ltd. MH, YK, and SK reported no conflict of interest.
: This study was conducted in accordance with Japanese Ministerial Ordinance on Good Post-marketing Study Practice, which does not mandate institutional review board approval for each participating center or written informed consent from patients.
